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Abtract: The purpose of the present study was to investigate whether brain reward function decreases during withdrawal 
from nicotine and methamphetamine, and whether decreased reward function is related to aversion during withdrawal 
from these drugs. For that purpose, male Sprague-Dawley rats were chronically infused subcutaneously with 9 mg/kg per 
day nicotine, or with 6 mg/kg per day methamphetamine using osmotic minipumps. In an intracranial self-stimulation 
(ICSS) paradigm, chronic infusion of nicotine and methamphetamine decreased the thresholds for lateral hypothalamic 
ICSS, whereas their antagonists, mecamylamine and haloperidol increased the ICSS thresholds in the rats treated with 
nicotine and methamphetamine, respectively. In a conditioned place aversion paradigm, mecamylamine and haloperidol 
produced place aversion in nicotine- and methamphetamine-infused rats, respectively. Interestingly, elevations in ICSS 
reward thresholds and place aversion during mecamylamine-precipitated nicotine withdrawal were almost the same in 
magnitude as those observed during haloperidol-precipitated methamphetamine withdrawal. The present study indicates 
that 1) brain reward function decreased during nicotine and methamphetamine withdrawal, and 2) a decrease in reward 
function may reflect the negative affective state (aversion) during withdrawal from nicotine and methamphetamine. 
Keywords: Nicotine, methamphetamine, intracranial self-stimulation, conditioned place aversion, brain reward system,   
withdrawal. 
1. INTRODUCTION 
  Clinical evidence indicates that the affective signs of 
abstinence syndrome may be more relevant to drug craving 
and relapse to compulsive drug use than the somatic signs of 
withdrawal [1-3]. For that reason, the affective aspects of 
drug dependence have been extensively investigated using 
various kinds of experimental paradigms. Among them, the 
technique of intracranial self-stimulation (ICSS) is widely 
used to measure brain reward function. In animal studies, 
acute administration of a drug of abuse decreases ICSS re-
ward thresholds [4, 5] and this increased sensitivity to the 
stimulation is considered a measure of drug-induced eupho-
ria [6]. Furthermore, it is hypothesized that ICSS reward may 
be attenuated following repeated administration of a drug of 
abuse, resulting from neuroadapted changes of brain reward 
systems, and reflect dysphoria during withdrawal from the 
drug [7, 8]. Many studies have demonstrated elevations in 
ICSS reward thresholds during withdrawal from various 
kinds of drugs of abuse including amphetamine [9], cocaine 
[6], opiates [10], ethanol [11], and nicotine [12], all of which 
support the aforementioned hypothesis. Therefore, the pre-
sent study was designed to clarify whether elevations in 
ICSS reward thresholds are related to the negative affective 
state of withdrawal, specifically focusing on two different 
types of psychostimulants, nicotine and methamphetamine.  
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2. MATERIALS AND METHODS 
2.1. Animals 
  Seventy-two male Sprague-Dawley rats (332-396 g)   
obtained from Clea Japan Inc. (Tokyo) were individually 
housed in an animal room at a regulated temperature (22 ± 2 ºC) 
with a light/dark cycle of 12/12 hours (light on at 8:00 
A.M.). Each rat was fed 15 g of food per day (water freely 
available) throughout the experiment, except for a period of 
3 days before and 7 days after surgery. This experiment was 
performed in accordance with the Principles of Laboratory 
Animal Care of Jikei University School of Medicine. 
2.2. Drugs 
  (-)-nicotine hydrogen tartrate (Sigma, St. Louis,   
MO, USA), mecamylamine hydrochloride (Sigma), (-) meth-
amphetamine hydrochloride (Dainipponn Seiyaku, Japan), 
and haloperidol hydrochloride (Sigma) were dissolved in 
saline and injected in a volume of 1.0 ml/kg. 
2.3. Intracranial Self-Stimulation 
2.3.1. Apparatus 
  A standard operant chamber of 29.5 (W) x 23.5 (L) x 
28.7 (H) cm (ENV-008; Med Associates, Inc., St. Albans, 
VT, USA) equipped with one lever and a cue light above the 
lever on the front wall and a house light on the rear wall was 
used. Sidewalls were made of transparent Plexiglas. 
2.3.2. Surgery 
  Rats were anesthetized with sodium pentobarbital 
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lar electrode (Neuroscience, Japan) in the lateral hypothala-
mus (coordinates 3.8mm posterior to bregma; 1.4mm lateral 
to midline; 8.4mm ventral to dura) according to the atlas of 
Paxinos and Watson [13]. To counterbalance any possible 
brain asymmetries, half the rats received implants on the 
right side of the brain, with the other on the left side. 
2.3.3. Procedure 
  In the ICSS training sessions, a house light and a cue 
light were turned on and the electrical stimuli were given 
each time immediately after the rat pressed the lever. The 
stimuli consisted of 1.5 msec rectangular cathodal pulses, 
delivered by 100 Hz for 150 msec with a fixed current of 120 
μA. Each training session lasted for 15 min. ICSS training 
was given at least for 6 days and continued until the number 
of lever press was more than 30 per min for 3 consecutive 
days. 
  To measure the baseline of ICSS responding, baseline 
test was performed for 15 min before each ICSS threshold 
test. The procedure of the baseline test was the same as in the 
ICSS training. An ICSS threshold test was composed of 11 
time bins of 3 min separated by 1 min time out. During the 
time out, a house light and a cue lamp were turned off. In 
each test bin, these lights were turned on and the rats re-
ceived the electrical stimulation after each lever press. 
Across the bins, the electric stimulation current was de-
creased by 10 μA from 120 μA to 20 μA in a descending 
order. 
  Stable baseline of ICSS responding was established for 
all rats before implantation of the minipumps. On day 1, an 
osmotic minipump (Alzet 2001, Alza Corporation, CA, 
USA) with a flow rate of 1.03 μl/h filled with nicotine or 
methamphetamine in saline was subcutaneously implanted in 
rats that had been anesthetized with diethylether. The con-
centration of nicotine and methamphetamine was adjusted 
for differences in body weight, but was approximately 116 
and 77.3 mg/ml, resulting in continuous subcutaneous infu-
sion at the rate of 9 mg/kg per day of nicotine and at the rate 
of 6 mg/kg per day of methamphetamine according to the 
method of a previous study [14]. The ICSS threshold test 
was conducted on day 2, 4, and 6 after implantation of the 
minipumps. 
  On day 7 after minipump implantation, rats received me-
camylamine (0.0, 0.1, 0.5, 1.0 mg/kg, s.c.) in the nicotine- 
and saline-infused groups, or haloperidol (0.0, 0.1, 0.25, 0.5 
mg/kg, s.c.) in the methamphetamine- and saline-infused 
groups, 15 min before the beginning of the ICSS threshold 
test session, using a within-subjects Latin-square design. 
Animals were required to return to baseline ICSS threshold 
levels for at least one ICSS session before subsequent   
antagonist or vehicle injections. 
2.3.4. Histology 
  Rats were sacrificed by deep anesthesia by sodium   
pentobarbital. The brain was removed and stored in 10% 
formaldehyde solution. Brain was sliced at a thickness of 
100  μm and the tip of an electrode was microscopically   
examined. 
2.4. Condition Place Aversion 
2.4.1. Appatarus 
  Place conditioning was conducted according to the 
method of Suzuki et al. [15, 16]. The apparatus consisted of 
a shuttlebox (306030 cm: wlh) which was divided into 
two compartments of equal size. One compartment was 
white with a textured floor and the other was black with a 
smooth floor. 
2.4.2. Procedure 
  On day 1, rats were prepared with nicotine-, metham- 
phetamine-, or saline-containing osmotic minipumps under 
the same conditions as those described for the ICSS study. 
  In the morning (9:00) on day 7 of nicotine or metham-
phetamine infusion, rats were subcutaneously injected with 
an antagonist of the test drug (mecamylamine or haloperi-
dol), or saline (1.0 ml/kg), and immediately confined to one 
compartment of the test apparatus for 60 min. In the evening 
(21:00) on the same day, rats were then treated with saline or 
an antagonist (mecamylamine or haloperidol), respectively, 
and confined to the other compartment for 60 min. The pair-
ings of injection (antagonist or saline) and compartment 
(white or black) were counterbalanced across all of the sub-
jects. The control rats in the nicotine-, methamphetamine-, 
and saline-infused groups were injected with saline instead 
of mecamylamine or haloperidol in the conditioning session. 
After the saline injections, the rats were confined to one 
compartment in the morning and to the other compartment in 
the evening. 
  In the morning on day 8, tests of conditioning were per-
formed as follows: the partition which separated the two 
compartments was raised to 12 cm above the floor, and a 
neutral platform was inserted along the seam separating the 
compartments. The time spent in each compartment during a 
900-s session was measured automatically by an infrared 
beam sensor (kn-80, Natsyme Seisakusho, Tokyo, Japan). 
2.5. Assessment of Somatic Withdrawal Signs 
  In the ICSS experiment, each rat was placed into a cylin-
drical plastic observation chamber immediately after termi-
nation of the ICSS reward threshold session following ad-
ministration of mecamylamine or haloperidol, and somatic 
withdrawal signs were observed for 10 min. During assess-
ment of somatic withdrawal signs, the frequency of absti-
nence symptoms was recorded using an opiate-abstinence 
scale modified to score nicotine or methamphetamine absti-
nence [1]. Experimenters were blind to the treatment of each 
rat. In the CPP experiment, somatic withdrawal signs were 
observed in the same manner as that in the ICSS experiment 
except for the fact that observation of somatic abstinence 
signs was conducted in the CPP apparatus. 
2.6. Data Analysis 
  For the measure of the ICSS responding, number of rein-
forcement per min in each bin was used as the measure. On 
test days, the number of reinforcements at each electric cur-
rent was converted into percentage of the baseline obtained 
on that day. To determine the ICSS threshold, S-shape curve Decreases in Brain Reward Function Reflect                         Current Neuropharmacology, 2011, Vol. 9, No. 1    65 
was individually fitted according to the sigmoid-Gompertz 
model. Using this model, the electric current inducing 50% 
of baseline responding was determined as the ICSS thresh-
old. All data were analyzed using a two-way within-subjects 
repeated-measures analysis of variance (ANOVA) followed 
by Tukey’s Studentized Range Method after observation of a 
statistically significant effect of treatment conditions in the 
ANOVA. 
  Conditioning scores represent the time spent in the drug-
paired place minus the time spent in the vehicle-paired place 
and are expressed as the mean ± S.E.M. Behavioral data 
were statistically evaluated with a two-way repeated-
measures ANOVA, which was used to determine the effects 
of treatment on antagonist-induced place conditioning. When 
the ANOVA indicated the presence of a significant effect, 
further analysis was conducted with Tukey’s Studentized 
Range Method. 
3. RESULTS 
3.1. ICSS Thresholds 
  During chronic administration, nicotine (F (2, 35)=5.28, 
P<0.01) and methamphetamine (F  (2, 35)=7.62, P<0.01) 
significantly decreased ICSS reward thresholds. Individual 
means comparisons revealed significant effects on day 4 and 
day 5 of nicotine infusion (P<0.05), and on day 2, day 4, and 
day 5 of methamphetamine infusion (P<0.05). 
  As shown in Fig. (1), in chronic nicotine-infused and 
methamphetamine-infused rats, mecamylamine (F (1, 47)= 
9.59,  P<0.01) and haloperidol (F  (1, 47)=10.64, P<0.01) 
produced significant elevations in ICSS reward thresholds, 
respectively. Individual means comparisons revealed signifi-
cant effects at 1.0 mg/kg mecamylamine (P<0.05) and at 
0.25 and 0.5 mg/kg haloperidol (P<0.05). There was no sig-
nificant effect of dose either in nicotine-infused rats (F (3, 
47)=1.87,  P>0.05) or in methamphetamine-infused rats (F 
(3, 47)=2.24, P>0.05), or treatmentdose interaction either in 
nicotine-infused rats (F (3, 47)=1.56, P>0.05) or in metham-
phetamine-infused rats (F(3, 47)=1.77, P>0.05). 
3.2. Conditioned Place Aversion (CPA) 
As shown in Fig. (2), the saline-control rats exhibited no 
preference for either compartment. Mecamylamine and 
haloperidol did not produce either significant place prefer-
ence or place aversion in saline-infused rats. On the other 
hand, mecamtlamine (F (1, 47)=8.62, P<0.01) and haloperi-
dol (F  (1, 47)=11.28, P<0.01) produced place aversion in 
chronic nicotine- and methamphetamine-infused rats, respec-
tively. Significant place aversion was observed at 1.0 mg/kg 
mecamylamine (P<0.01) and at 0.25 and 0.5 mg/kg halop-
eridol (P<0.05 and P<0.01). There was no significant effect 
of dose either in nicotine-infused rats (F  (3, 47)=1.98, 
P>0.05) or in methamphetamine-infused rats (F  (3, 
47)=2.56,  P>0.05), or treatmentdose interaction either in 
nicotine-infused rats (F (3, 47)=1.74, P>0.05) or in metham-
phetamine-infused rats (F (3, 47)=2.28, P>0.05). 
3.3. Somatic Signs 
The overall number of somatic signs did not differ between 
nicotine- and saline-treated rats during mecamylamine   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Intracranial self-stimulation reward thresholds during 
withdrawal precipitated by mecamylamine (upper graph) and 
haloperidol (lower graph) in rats that were chronically infused with 
nicotine and methamphetamine, respectively. Each point represents 
the mean percent of baseline threshold with S.E.M of 6 rats. 
*P<0.05 vs. saline-treated control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Place conditioning produced by mecamylamine (upper 
graph) and haloperidol (lower graph) in rats that were chronically 
infused with nicotine and methamphetamine, respectively. Each 
point represents the mean conditioning score with S.E.M. of 6 rats. 
*P<0.05 vs. saline-treated control. 
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administration either in the ICSS experiment (F (1, 47)=2.02, 
P>0.05) or in the CPA experiment (F (1, 47)=1.87, P>0.05). 
Furthermore, they did not differ between methamphetamine- 
and saline-treated rats during haloperidol administration   
either in the ICSS experiment (F (1, 47)=1.53, P>0.05) or in 
the CPA experiment (F (1, 47)=2.33, P>0.05). 
3.4. Histological Analysis 
  The results of the histological analysis indicated that the 
electrode tips were located in the area of the lateral hypo-
thalamus, in an anterior/posterior range extending from -3.84 
mm to -4.20 mm from the bregma. There did not appear to 
be any differences between the electrode locations of control 
and experimental animals (Fig. 3). 
4. DISCUSSION 
  The results of the current study demonstrate that chronic 
administration of nicotine and methamphetamine decrease 
ICSS reward thresholds, whereas their antagonists, mecamy-
lamine and haloperidol increase ICSS reward thresholds and 
induce a CPA in rats treated with nicotine and metham-
phetamine, respectively. With regard to alterations in brain 
reward circuitry during withdrawal, it has been argued that, 
as dependence develops, neuroadaptations occur within the 
same brain circuits that mediate the reinforcing or rewarding 
effects of drugs of abuse following acute administration, 
leading to the expression of negative affective signs of with-
drawal upon drug abstinence [7, 8]. Consistent with this no-
tion, the present study indicated that nicotine as well as 
methamphetamine showed decreases in ICSS reward thresh-
olds during acute administration, and increases during an-
tagonist-precipitated withdrawal. Other drugs of abuse such 
as cocaine [6], opiates [10], and ethanol [11] have also been 
reported to induce similar pattern of effects on ICSS reward 
thresholds. A question as to whether such changes in brain 
reward circuitry are sufficient to account for the negative 
affective consequences of withdrawal has been under inves-
tigation. A paradigm of CPA is a useful and sensitive behav-
ioral index to detect withdrawal aversion, as reported in pre-
vious studies involving nicotine [15, 16] and opiates [17, 
10]. In the present study, mecamylamine and haloperidol 
induced a CPA at doses showing elevations in ICSS reward 
thresholds, suggesting that elevations in ICSS reward thresh-
old may mediate aversion during withdrawal from nicotine 
and methamphetamine. On the other hand, mecamylamine 
and haloperidol failed to induce somatic withdrawal signs. 
Somatic signs of withdrawal from psychostimulants are 
known to be weaker than those from opiates, barbiturates 
and alcohol. Furthermore, it is more difficult to observe so-
matic withdrawal signs precipitated by nicotine antagonists 
than those elicited by spontaneous withdrawal [12]. Interest-
ingly, in the present study, elevations in ICSS reward thresh-
olds and place aversion during nicotine withdrawal were 
almost the same in magnitude as those observed during 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Histological localization of lateral hypothalamic stimulating electrode tips. The number beside each brain slice represents the  
distance from the bregma. Reconstructions based on the stereotaxic atlas of Paxinos and Watson [13]. Placements that are completely over-
lapping are not shown. 
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methamphetamine withdrawal, which may suggest that de-
creases in brain reward function, leading to withdrawal aver-
sion, may not significantly differ in intensity between nico-
tine and methamphetamine, irrespective of acute effects of 
these drugs on the reward system. In other words, it is hy-
pothesized that neuroadaptations in brain reward circuitry 
develop almost to the same levels between nicotine and 
methamphetamine, although they stimulate the reward sys-
tem to a different degree with acute methamphetamine being 
stronger than acute nicotine. However, further studies are 
needed to clarify this question by employing a wider range 
of drug doses or other kinds of experimental paradigms. 
  In conclusion, the present study indicates that 1) brain 
reward function decreased during nicotine and metham-
phetamine withdrawal, and 2) a decrease in reward function 
may reflect the negative affective state (aversion) during 
withdrawal from nicotine and methamphetamine. 
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